journal article·2018-12-19Open access

Effect of nanoparticles on the expression and activity of matrix metalloproteinases

Magdalena Matysiak-Kucharek, Magdalena Czajka, Krzysztof Sawicki, Marcin Kruszewski, Lucyna Kapka-Skrzypczak

Nanotechnology Reviews· Volume 7· Issue 6

Abstract

Abstract Matrix metallopeptidases, commonly known as matrix metalloproteinases (MMPs), are a group of proteolytic enzymes whose main function is the remodeling of the extracellular matrix. Changes in the activity of these enzymes are observed in many pathological states, including cancer metastases. An increasing body of evidence indicates that nanoparticles (NPs) can lead to the deregulation of MMP expression and/or activity both in vitro and in vivo. In this work, we summarized the current state of knowledge on the impact of NPs on MMPs. The literature analysis showed that the impact of NPs on MMP expression and/or activity is inconclusive. NPs exhibit both stimulating and inhibitory effects, which might be dependent on multiple factors, such as NP size and coating or a cellular model used in the research.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Protease and Inhibitor Mechanisms · Peptidase Inhibition and Analysis · Studies on Chitinases and Chitosanases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Molecular Biology and Translational Research , Institute of Rural Health , Lublin, Jaczewskiego 2 , Lublin 20-090 , Poland

Centre for Radiobiology and Biological Dosimetry, Institute of Nuclear Chemistry and Technology , Dorodna 16 , Warsaw 03-195 , Poland

Department of Medical Biology and Translational Research, Faculty of Medicine , University of Information Technology and Management , Sucharskiego 2 , Rzeszów 35-225 , Poland

References (57)

Show source-provided references
1. Galliera E, Tacchini L, Romanelli MM. Matrix metalloproteinases as biomarkers of disease: updates and new insights. Clin. Chem. Lab. Med. 2015, 53, 349–355.10.1515/cclm-2014-0520 ↗
2. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011, 278, 16–27.10.1111/j.1742-4658.2010.07919.x ↗
3. Winer A, Adams S, Mignatti P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol. Cancer Ther. 2018, 17, 1147–1155.10.1158/1535-7163.MCT-17-0646 ↗
4. Boguszewska-Czubara A, Budzynska B, Skalicka-Wozniak K, Kurzepa J. Perspectives and new aspects of metalloproteinases’ inhibitors in therapy of CNS disorders: from chemistry to medicine. Curr. Med. Chem. 2018. [Epub ahead of print]. https://doi.org/10.2174/0929867325666180514111500.10.2174/0929867325666180514111500 ↗
5. Thakor AS, Gambhir SS. Nanooncology: the future of cancer diagnosis and therapy. CA Cancer J. Clin. 2013, 63, 395–418.10.3322/caac.21199 ↗
6. Bartłomiejczyk T, Lankoff A, Kruszewski M, Szumiel I. Silver nanoparticles – allies or adversaries? Ann. Agric. Environ. Med. 2013, 20, 48–54.
7. Czajka M, Sawicki K, Sikorska K, Popek S, Kruszewski M, Kapka-Skrzypczak L. Toxicity of titanium dioxide nanoparticles in central nervous system. Toxicol. In Vitro 2015, 29, 1042–1052.10.1016/j.tiv.2015.04.004 ↗
8. Bode W, Maskos K. Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Biol. Chem. 2003, 384, 863–872.10.1515/BC.2003.097 ↗
9. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 2003, 92, 827–839.10.1161/01.RES.0000070112.80711.3D ↗
10. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 2006, 69, 562–573.10.1016/j.cardiores.2005.12.002 ↗
11. Trojanek J. Matrix metalloproteinases and their tissue inhibitors. Postepy Biochem. 2012, 58, 353–362.
12. Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog. Mol. Biol. Transl. Sci. 2017, 147, 1–73.10.1016/bs.pmbts.2017.02.005 ↗
13. Bond M, Chase AJ, Baker AH, Newby AC. Inhibition of transcription factor NF-κB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc. Res. 2001, 50, 556–565.10.1016/S0008-6363(01)00220-6 ↗
14. Itoh M, Murata T, Suzuki T, Shindoh M, Nakajima K, Imai K, Yoshida K. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 2006, 25, 1195–1204.10.1038/sj.onc.1209149 ↗
15. Chernov AV, Strongin AY. Epigenetic regulation of matrix metalloproteinases and their collagen substrates in cancer. Biomol. Concepts 2011, 2, 135–147.10.1515/bmc.2011.017 ↗
16. Choo WH, Park CH, Jung SE, Moon B, Ahn H, Ryu JS, Kim KS, Lee YH, Yu IJ, Oh SM. Long-term exposures to low doses of silver nanoparticles enhanced in vitro malignant cell transformation in non-tumorigenic BEAS-2B cells. Toxicol. In Vitro 2016, 37, 41–49.10.1016/j.tiv.2016.09.003 ↗
17. Vila L, Marcos R, Hernández A. Long-term effects of silver nanoparticles in Caco-2 cells. Nanotoxicology 2017, 11, 771–780.10.1080/17435390.2017.1355997 ↗
18. Cramer S, Tacke S, Bornhorst J, Klingauf J, Schwerdtle T, Galla HJ. The influence of silver nanoparticles on the blood-brain and the blood-cerebrospinal fluid barrier in vitro. J. Nanomed. Nanotechnol. 2014, 5, 225.10.4172/2157-7439.1000225 ↗
19. Franková J, Pivodová V, Vágnerová H, Juráňová J, Ulrichová J. Effects of silver nanoparticles on primary cell cultures of fibroblasts and keratinocytes in a wound-healing model. J. Appl. Biomater. Funct. Mater. 2016, 14, e137–e142.10.5301/jabfm.5000268 ↗
20. Xu L, Shi C, Shao A, Li X, Cheng X, Ding R, Wu G, Chou LL. Toxic responses in rat embryonic cells to silver nanoparticles and released silver ions as analyzed via gene expression profiles and transmission electron microscopy. Nanotoxicology 2015, 9, 513–522.10.3109/17435390.2014.948942 ↗
21. Inkielewicz-Stepniak I, Santos-Martinez MJ, Medina C, Radomski MW. Pharmacological and toxicological effects of co-exposure of human gingival fibroblasts to silver nanoparticles and sodium fluoride. Int. J. Nanomed. 2014, 9, 1677–1687.10.2147/IJN.S59172 ↗
22. Park EJ, Yi J, Kim Y, Choi K, Park K. Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism. Toxicol. In Vitro 2010, 24, 872–878.10.1016/j.tiv.2009.12.001 ↗
23. Poirier M, Simard JC, Girard D. Silver nanoparticles of 70nm and 20nm affect differently the biology of human neutrophils. J. Immunotoxicol. 2016, 13, 375–385.10.3109/1547691X.2015.1106622 ↗
24. Brzóska K, Męczyńska-Wielgosz S, Stępkowski TM, Kruszewski M. Adaptation of HepG2 cells to silver nanoparticles-induced stress is based on the pro-proliferative and anti-apoptotic changes in gene expression. Mutagenesis 2015, 30, 431–439.10.1093/mutage/gev001 ↗
25. Pascarelli NA, Moretti E, Terzuoli G, Lamboglia A, Renieri T, Fioravanti A, Collodel G. Effects of gold and silver nanoparticles in cultured human osteoarthritic chondrocytes. J. Appl. Toxicol. 2013, 33, 1506–1513.10.1002/jat.2912 ↗
26. Liu Z, Wu Y, Guo Z, Liu Y, Shen Y, Zhou P, Lu X. Effects of internalized gold nanoparticles with respect to cytotoxicity and invasion activity in lung cancer cells. PLoS One 2014, 9, e99175.10.1371/journal.pone.0099175 ↗
27. Babin K, Antoine F, Goncalves DM, Girard D. TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils. Toxicol. Lett. 2013, 221, 57–63.10.1016/j.toxlet.2013.05.010 ↗
28. Wan R, Mo Y, Zhang X, Chien S, Tollerud DJ, Zhang Q. Matrix metalloproteinase-2 and -9 are induced differently by metal nanoparticles in human monocytes: the role of oxidative stress and protein tyrosine kinase activation. Toxicol. Appl. Pharmacol. 2008, 233, 276–285.10.1016/j.taap.2008.08.022 ↗
29. Annangi B, Bach J, Vales G, Rubio L, Marcos R, Hernández A. Long-term exposures to low doses of cobalt nanoparticles induce cell transformation enhanced by oxidative damage. Nanotoxicology 2015, 9, 138–147.10.3109/17435390.2014.900582 ↗
30. Pacurari M, May I, Tchounwou PB. Effects of lipopolysaccharide, multiwalled carbon nantoubes, and the combination on lung alveolar epithelial cells. Environ. Toxicol. 2017, 32, 445–455.10.1002/tox.22248 ↗
31. Wan R, Mo Y, Chien S, Li Y, Li Y, Tollerud DJ, Zhang Q. The role of hypoxia inducible factor-1α in the increased MMP-2 and MMP-9 production by human monocytes exposed to nickel. Nanotoxicology 2011, 5, 568–582.10.3109/17435390.2010.537791 ↗
32. McCarthy J, Inkielewicz-Stępniak I, Corbalan JJ, Radomski MW. Mechanisms of toxicity of amorphous silica nanoparticles on human lung submucosal cells in vitro: protective effects of fisetin. Chem. Res. Toxicol. 2012, 25, 2227–2235.10.1021/tx3002884 ↗
33. Armand L, Dagouassat M, Belade E, Simon-Deckers A, Le Gouvello S, Tharabat C, Duprez C, Andujar P, Pairon JC, Boczkowski J, Lanone S. Titanium dioxide nanoparticles induce matrix metalloprotease 1 in human pulmonary fibroblasts partly via an interleukin-1β-dependent mechanism. Am. J. Respir. Cell. Mol. Biol. 2013, 48, 354–363.10.1165/rcmb.2012-0099OC ↗
34. Wu Y, Zhang Q, Ruan Z, Yin Y. Intrinsic effects of gold nanoparticles on proliferation and invasion activity in SGC-7901 cells. Oncol. Rep. 2016, 35, 1457–1462.10.3892/or.2015.4474 ↗
35. Zhang Q, Ma Y, Yang S, Xu B, Fei X. Small-sized gold nanoparticles inhibit the proliferation and invasion of SW579 cells. Mol. Med. Rep. 2015, 12, 8313–8319.10.3892/mmr.2015.4433 ↗
36. Hashimoto M, Yamaguchi S, Sasaki J, Kawai K, Kawakami H, Iwasaki Y, Imazato S. Inhibition of matrix metalloproteinases and toxicity of gold and platinum nanoparticles in L929 fibroblast cells. Eur. J. Oral Sci. 2016, 124, 68–74.10.1111/eos.12235 ↗
37. Hashimoto M, Kawai K, Kawakami H, Imazato S. Matrix metalloproteases inhibition and biocompatibility of gold and platinum nanoparticles. J. Biomed. Mater. Res. A 2016, 104, 209–217.10.1002/jbm.a.35557 ↗
38. Hashimoto M, Sasaki JI, Yamaguchi S, Kawai K, Kawakami H, Iwasaki Y, Imazato S. Gold nanoparticles inhibit matrix metalloproteases without cytotoxicity. J. Dent. Res. 2015, 94, 1085–1091.10.1177/0022034515589282 ↗
39. Liu Q, Jin L, Shen FH, Balian G, Li XJ. Fullerol nanoparticles suppress inflammatory response and adipogenesis of vertebral bone marrow stromal cells – a potential novel treatment for intervertebral disc degeneration. Spine J. 2013, 13, 1571–1580.10.1016/j.spinee.2013.04.004 ↗
40. Meng H, Xing G, Blanco E, Song Y, Zhao L, Sun B, Li X, Wang PC, Korotcov A, Li W, Liang XJ, Chen C, Yuan H, Zhao F, Chen Z, Sun T, Chai Z, Ferrari M, Zhao Y. Gadolinium metallofullerenol nanoparticles inhibit cancer metastasis through matrix metalloproteinase inhibition: imprisoning instead of poisoning cancer cells. Nanomedicine 2012, 8, 136–146.10.1016/j.nano.2011.08.019 ↗
41. Shakibaie M, Khorramizadeh MR, Faramarzi MA, Sabzevari O, Shahverdi AR. Biosynthesis and recovery of selenium nanoparticles and the effects on matrix metalloproteinase-2 expression. Biotechnol. Appl. Biochem. 2010, 56, 7–15.10.1042/BA20100042 ↗
42. Yassin AM, Elnouby M, El-Deeb NM, Hafez EE. Tungsten oxide nanoplates; the novelty in targeting metalloproteinase-7 gene in both cervix and colon cancer cells. Appl. Biochem. Biotechnol. 2016, 180, 623–637.10.1007/s12010-016-2120-x ↗
43. Guo da D, Li QN, Li CM, Bi HS. Zinc oxide nanoparticles inhibit murine photoreceptor-derived cell proliferation and migration via reducing TGF-β and MMP-9 expression in vitro. Cell Prolif. 2015, 48, 198–208.10.1111/cpr.12163 ↗
44. Park EJ, Kim H, Kim Y, Park K. Intratracheal instillation of platinum nanoparticles may induce inflammatory responses in mice. Arch. Pharm. Res. 2010, 33, 727–735.10.1007/s12272-010-0512-y ↗
45. Park EJ, Kim H, Kim Y, Yi J, Choi K, Park K. Inflammatory responses may be induced by a single intratracheal instillation of iron nanoparticles in mice. Toxicology 2010, 275, 65–71.10.1016/j.tox.2010.06.002 ↗
46. Blum JL, Rosenblum LK, Grunig G, Beasley MB, Xiong JQ, Zelikoff JT. Short-term inhalation of cadmium oxide nanoparticles alters pulmonary dynamics associated with lung injury, inflammation, and repair in a mouse model. Inhal. Toxicol. 2014, 26, 48–58.10.3109/08958378.2013.851746 ↗
47. Ma JY, Mercer RR, Barger M, Schwegler-Berry D, Scabilloni J, Ma JK, Castranova V. Induction of pulmonary fibrosis by cerium oxide nanoparticles. Toxicol. Appl. Pharmacol. 2012, 262, 255–264.10.1016/j.taap.2012.05.005 ↗
48. Ma J, Mercer RR, Barger M, Schwegler-Berry D, Cohen JM, Demokritou P, Castranovac V. Effects of amorphous silica coating on cerium oxide nanoparticles induced pulmonary responses. Toxicol. Appl. Pharmacol. 2015, 288, 63–73.10.1016/j.taap.2015.07.012 ↗
49. Ambalavanan N, Stanishevsky A, Bulger A, Halloran B, Steele C, Vohra Y, Matalon S. Titanium oxide nanoparticle instillation induces inflammation and inhibits lung development in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2013, 304, L152–L161.10.1152/ajplung.00013.2012 ↗
50. Morimoto Y, Oyabu T, Ogami A, Myojo T, Kuroda E, Hirohashi M, Shimada M, Lenggoro W, Okuyama K, Tanaka I. Investigation of gene expression of MMP-2 and TIMP-2 mRNA in rat lung in inhaled nickel oxide and titanium dioxide nanoparticles. Ind. Health 2011, 49, 344–352.10.2486/indhealth.MS1218 ↗
51. Chang XH, Zhu A, Liu FF, Zou LY, Su L, Liu SK, Zhou HH, Sun YY, Han AJ, Sun YF, Li S, Li J, Sun YB. Nickel oxide nanoparticles induced pulmonary fibrosis via TGF-β1 activation in rats. Hum. Exp. Toxicol. 2017, 36, 802–812.10.1177/0960327116666650 ↗
52. Opris R, Tatomir C, Olteanu D, Moldovan R, Moldovan B, David L, Nagy A, Decea N, Kiss ML, Filip GA. The effect of Sambucus nigra L. extract and phytosynthesized gold nanoparticles on diabetic rats. Colloids Surf. B Biointerfaces 2017, 150, 192–200.10.1016/j.colsurfb.2016.11.033 ↗
53. Medhat A, Mansour S, El-Sonbaty S, Kandil E, Mahmoud M. Evaluation of the antitumor activity of platinum nanoparticles in the treatment of hepatocellular carcinoma induced in rats. Tumour Biol. 2017, 39, 1010428317717259.10.1177/1010428317717259 ↗
54. Yanhua W, Hao H, Li Y, Zhang S. Selenium-substituted hydroxyapatite nanoparticles and their in vivo antitumor effect on hepatocellular carcinoma. Colloids Surf. B Biointerfaces 2016, 140, 297–306.10.1016/j.colsurfb.2015.12.056 ↗
55. Kang SG, Zhou G, Yang P, Liu Y, Sun B, Huynh T, Meng H, Zhao L, Xing G, Chen C, Zhao Y, Zhou R. Molecular mechanism of pancreatic tumor metastasis inhibition by Gd@C82(OH)22 and its implication for de novo design of nanomedicine. Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 15431–15436.10.1073/pnas.1204600109 ↗
56. Ma J, Liu J, Lu CW, Cai DF. Pachymic acid modified carbon nanoparticles reduced angiogenesis via inhibition of MMP-3. Int. J. Clin. Exp. Pathol. 2015, 8, 5464–5470.
57. Kang SG, Araya-Secchi R, Wang D, Wang B, Huynh T, Zhou R. Dual inhibitory pathways of metallofullerenol Gd@C82(OH)22 on matrix metalloproteinase-2: molecular insight into drug-like nanomedicine. Sci. Rep. 2014, 4, 4775.10.1038/srep04775 ↗